Author Topic: OWCP (Read 2745 times)

Clay Death · « **on:** October 11, 2016, 06:19:09 pm »

http://www.cnbc.com/2016/10/11/pr-newswire-owc-pharmaceutical-research-corp-to-initiate-efficacy-testing-on-its-cannabinoid-infused-cream-for-treatment-of-psoriasis.html

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it is starting the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions.

(Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )

(Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

The Company's recently completed Challenge Testing for the topical crème, successfully demonstrated the product's robustness against microbiological contamination, stability, and provided a preliminary safety assessment. This next phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. This will be demonstrated by giving a highly concentrated topical crème formulation to healthy patients within a hospital controlled environment. The safety phase will start upon receiving the Institutional Review Board (IRB) approval by the national IRB committee which is expected to be assembled in November 2016.

OWC is also preparing to initiate in parallel Efficacy Testing using MatTek Corporation patented EpiDerm™ system, an in-vitro testing technology for dermal toxicologists. This protocol will seek to prove the effectiveness of the formulation in treating psoriasis on human skin tissue. The tests will be conducted at an approved international lab of Dead Sea & Arava Science Center under the auspices of the Ben-Gurion University of the Negev (http://www.adssc.org/ ).

Dr. Yehuda Baruch, the Company's Director of Research and Regulatory Affairs, commented on the announcement, "Psoriasis is an affliction of the immune system resulting in sub-dermal infection that can be painful and uncomfortable. Cannabis is believed to provide relief from some infections and skin conditions, and it is a central ingredient in our topical crème formulation. Our preliminary studies indicate the formulation does provide relief of these symptoms, and we are confident that these studies will corroborate those results."

Ziv Turner, OWC's CEO, went on to say, "We are excited to begin this last phase of testing so that we can finally make this product available for all psoriasis sufferers. We hope to start sales and marketing both in Israel the US in the second quarter of 2017, and have already been in contact with a number of representatives who have expressed interest in manufacturing and distributing the crème in their state. Of course, we also continue our work on multiple myeloma and other conditions, so I am hopeful that this is just the first of many products that will follow."

Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development. According to the National Psoriasis Foundation, psoriasis affects 7.5 million people in the United States.

About OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/

Clay Death · « **Reply #1 on:** October 29, 2016, 08:21:15 pm »

http://www.cannabisfn.com/cfnvideo/?id=sLXXiKPI

Clay Death · « **Reply #2 on:** October 30, 2016, 05:29:16 pm »

https://www.insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-has-enough-catalysts-to-hold-onto-its-gains-and-more/117864/

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Has Enough Catalysts To Hold Onto Its Gains And More

By Chris Sandburg / in Biotech & Pharma, Momentum Stocks, Sector Watch, Stocks / on Thursday, 27 Oct 2016 09:25 PM /

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has been on an incredible run as late. The company kicked off the month trading for around $0.015 share. Early this week, OWC went for $0.15 share – a 900% gain across the period. The last couple of sessions has seen the company give back a portion of these gains, and we think this might be a nice opportunity to prick up an exposure on the pullback.

Here’s what we’re looking at.

First, and for those not familiar with the company, let’s kick things off with a brief introduction. OWC is the parent company of wholly owned subsidiary, One World Cannabis Ltd. The entity reports through OWC, but operates under the One World sub. As a quick note, this One World brand is mistakenly listed on a number of the major financial sites as One Word – overlook the error, it’s the same brand.

The company’s goal is to enter the cannabis pharmaceutical space, through the application of the standard pharmaceutical development framework (rigorous testing, application for approval etc.) to various incarnations of the cannabis plant and its active compounds.

Through a few collaboration agreements, all of which are rooted in a primary collaboration with the leading Israeli medical center and research hospital, Sheba, it is targeting three initial indications: psoriasis, fibromyalgia and multiple myeloma. There are a couple of secondary target indications lower down the pipeline – PTSD and migraines – but for the purposes of this discussion (i.e. what’s going to drive near term value) we can overlook these for now.

So, what’s behind the recent gains?

Well, we’ve mentioned this on numerous occasions this week – the cannabis sector is on fire. The upcoming legalization vote out of California has had investors scrambling for an exposure to the growth, and companies across the board are picking up strength. This is the primary driver behind the action we’ve seen this month, and it’s turned OWC in to a top momentum pick as late.

We’re not subscribing to the hysteria, however. We’re looking for companies that are likely to hold on to gains after the excitement dies down. Whatever happens in California, a large portion of the companies gaining strength right now are going to crash (of course, this crash is going to be more severe if Californian’s vote against the ballot). As such, we want companies with near term catalysts that can help provide a floor to the correction, and going forward, serve as a platform from which to build post-hysteria momentum.

OWC’s three pronged pipeline meets these criteria.

The first catalyst on our watch list is the initiation of a clinical program in the company’s psoriasis topical treatment. In vitro studies are complete, and OWC expects to kick off a healthy volunteer study at the above mentioned Sheba at some point early November. With this sort of treatment, the path to market is very short. As long as the company can prove the medication safe, it can start commercialization in the US and Israel concurrently. Safety is based on the just mentioned trial, so managements expects sales to start rolling in as soon as the second quarter of next year.

Looking at myeloma (which OWC bills as its most advanced program) there’s not a whole lot of detail available as to progress, but we know the following. First, pre-clinically, the company demonstrated that some combinations of THC and CBD led to the eradication of 100% of myeloma cells in 60% of tested cultured cells within 24 to 48 hours of exposure to the cannabinoid formulation.

In the latest 10Q, OWC stated it would kick off a clinical study in first quarter 2016, but an update in May detailed the completion of some mouse studies, and the following quote is essentially all we’ve got to go on:

““We hope that the efficacy and safety will give us the comfort we need to continue on to the human stage of testing.” Dr. Yehuda Baruch, OWC’s Director of Research.

We are looking at the next update on this program before the close of the year, and we expect some upside momentum if the company can present a protocol and – in turn – a potential pathway to the clinic.

Finally, we’re looking at progress in a sublingual tablet to provide what we might refer to as bread and butter upside. It’s not going to be a game changer, but the program should provide a nice steady stream of positive press releases. In turn, it should help to support the floor we discussed a little earlier.

Clay Death · « **Reply #3 on:** November 03, 2016, 08:36:27 pm »

OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Initial Focus Will Be Commercialization of Company's Topical Psoriasis Treatment in the European Union

http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-signs-investment-and-joint-venture-with-michepro-holdings-ltd-599813021.html

OWC Pharmaceutical Research Corp Signs Investment and Joint Venture with Michepro Holdings Ltd
Initial Focus Will Be Commercialization of Company's Topical Psoriasis Treatment in the European Union

NEWS PROVIDED BY
OWC Pharmaceutical Research Corp.
Nov 03, 2016, 08:21 ET

PETACH TIKVA, Israel, November 3, 2016 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWCP" or the "Company"), through its Israeli based fully owned subsidiary, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced it has inked agreement for a combined JV & Private Placement of $300,000 with Michepro Holding Ltd a private family investment company organized under the laws of the state of Cyprus ("The Investor\ partner ").

The Investor will be issued with 2,307,692 restricted shares of the Company's common stock (a price of $0.13 per share) with additional warrants to purchase 761,538 restricted shares at an exercise price of $0.25 per share for a period of 24 months, and additional warrants for 761,538 restricted shares at an exercise price of $0.40 per share for a period of 36 months. In addition to the investment, the parties will establish a joint venture, 75% to OWCP and 25% to Michepro Holding Ltd to promote, sell, market and distribute the Company's potential products in Europe, initially with the psoriasis treatment, to be followed with company's other therapies as they become available."

Continue Reading
Cannabinoids-enriched innovative delivery systems by One World Cannabis. A soluble tablets for sublingual use as a smoke-free alternative, and a topical crÃ¨me designated for skin diseases starting with Psoriasis.

Cannabinoids-enriched innovative delivery systems by One World Cannabis. A soluble tablets for sublingual use as a smoke-free alternative, and a topical crÃ¨me designated for skin diseases starting with Psoriasis.

Cannabinoids-enriched innovative delivery systems by One World Cannabis. A soluble tablets for sublingual use as a smoke-free alternative, and a topical crÃ¨me designated for skin diseases starting with Psoriasis. (PRNewsFoto/OWC Pharmaceutical Research Corp)OWCP Logo
The World Health Organization's 2016 Global Report on Psoriasis states that psoriasis is a serious global problem affecting at least 100 million individuals worldwide. The report indicates the prevalence of psoriasis ranges from 0.09% in countries with warmer climates to 11.43% in Norway, where a colder climate prevails. The European market for psoriasis is estimated to be 15-20 Million patients.

Mr. Mordechai Bignitz, OWCP's Chairman and CEO, commented on the announcement, "We are excited to partner with Michepro Holding Ltd. The investment proceeds will be used to accelerate development of several of OWCP's products and support international marketing activities". Mr. Bignitz went on to say: "the recent activity in OWC stock has given rise to numerous investment proposals, but after reviewing the options we believe that Michepro Holding Ltd represents the best opportunity for the Company and our shareholders. Their EU business development experience and marketing expertise, as well as their enthusiasm about our future as a company are very encouraging, and it is the perfect follow-up to the agreement with signed with MedMar for the US."

Mr. Bignitz competed, "We believe the European market represents a substantial opportunity. Medical cannabis is already administrated in some countries in Europe, with several markets indicating they are on the brink of approval. Our initial focus will be the Netherlands, Czech Republic, Italy, Germany and the UK."

Commenting on his investment, Mr. Michael Brath a Director of Michepro Holding Ltd said, "OWC is the perfect match to our investment strategy; they are pioneers in the field of medical cannabis clinical research and we see incredible value in the work they are doing which is exactly what has been missing from thisMMJ market. We decided to invest and partner with them because I believe that our resources across the EU will significantly accelerate their ability to commercialize those efforts throughout that market - initially with the psoriasis treatment, and then with other therapies as they come online"

Psoriasis is an autoimmune disease that causes red, scaly patches to appear on the skin, and can be associated with other serious health conditions, including diabetes, heart disease and depression. Skin cells in patients with psoriasis grow at an abnormally fast rate, causing a buildup of lesions that tend to burn and itch. While the real cause of psoriasis is not known, genetics are believed to play a major role in its development.

About OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information:
In Israel:
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972-(0)3-7582659

In the United States:
Jeffrey Friedland
Email: Jfriedland@owcpharma.com
Tel: +1-(646)-450-8909
SOURCE OWC Pharmaceutical Research Corp.

Opportunity is Everywhere. Take Advantage by Opening an E*TRADE Account.Advertisement
.

Clay Death · « **Reply #4 on:** November 05, 2016, 09:30:29 pm »

https://www.insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-consolidating-before-heading-higher/118094/

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Consolidating Before Heading Higher

By Alex Carlson / in Biotech & Pharma, Momentum Stocks, Sector Watch, Stocks / on Friday, 04 Nov 2016 02:55 AM / 0 Comment / 487 views

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has been one of the biggest winners for investors in the cannabis space. OWCP was trading as low as $.0030 at the end of September before turning into a microcap runner last month and hitting highs of $.2150 on October 24. Now, OWCP has pulled back on profit taking and looks to consolidate before resuming its push higher. In looking at the news coming out of the company, we believe there are a number of upcoming catalysts that will put OWCP back on the trajectory of hitting new daily highs.

First up, a little background on the company. OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

The run-up in OWCP has allowed the company to raise money at higher levels and avoid painful dilution. OWCP just signed an investor agreement for a combined JV & Private Placement of $300,000 with Michepro Holding Ltd, a private family investment company. The Investor will be issued with 2,307,692 restricted shares of the Company’s common stock (a price of $0.13 per share) with additional warrants to purchase 761,538 restricted shares at an exercise price of $0.25 per share for a period of 24 months, and additional warrants for 761,538 restricted shares at an exercise price of $0.40 per share for a period of 36 months.

In addition to the investment, the parties will establish a joint venture, 75% to OWCP and 25% to Michepro Holding Ltd to promote, sell, market and distribute the Company’s potential products in Europe, initially with the psoriasis treatment, to be followed with company’s other therapies as they become available. Chairman and CEO Mordechai Bignitz said:

“ “We are excited to partner with Michepro Holding Ltd. The investment proceeds will be used to accelerate development of several of OWCP’s products and support international marketing activities. We believe the European market represents a substantial opportunity. Medical cannabis is already administrated in some countries in Europe, with several markets indicating they are on the brink of approval. Our initial focus will be the Netherlands, Czech Republic, Italy, Germany and the UK.”

Last month, OWCP completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through oral epithelial tissue. The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.

OWCP is working towards having the Tablet approved by the Israeli Medicinal Cannabis Unit under the Ministry of Health office for use within the country’s sanctioned medical cannabis program, as well as talking with potential licensees of the technology in the United States. Longer term, management expects to establish clinical tests of the Tablet in protocols for Multiple Myeloma, Post-Traumatic Stress Disorder (PTSD), and Fibromyalgia.

Going forward, we expect news coming from the company regarding the final phase for testing the efficacy of its own developed topical crème compound for the treatment of psoriasis and related skin conditions. The Company’s recently completed Challenge Testing for the topical crème, successfully demonstrated the product’s robustness against microbiological contamination, stability, and provided a preliminary safety assessment. This next phase of Safety testing protocol was designed to corroborate that the cream is safe for application to the skin. This will be demonstrated by giving a highly concentrated topical crème formulation to healthy patients within a hospital controlled environment. The safety phase will start upon receiving the Institutional Review Board (IRB) approval by the national IRB committee which is expected to be assembled in November 2016. Sales and marketing for the product in both Israel and the U.S. is expected by the second quarter of 2017.

Currently trading with a market cap of $16.9 million, there are 135,305,474 outstanding shares and 86,515,750 shares in the float according to the latest data from OTC Markets. While the float is not as tight as it was in September, consider that the 30 day average daily volume has been almost 17 million shares. As of October 15, there were almost 1 million shares short and we think this number has picked up considerably. There’s still plenty of shorts left to be squeezed and push OWCP higher. With the news flow coming out of Israel, we believe this will be happening sooner rather than later.

We will be updating our subscribers as soon as we know more. For the latest updates on OWCP, sign up below!

Sign up for next microcap

Clay Death · « **Reply #5 on:** November 08, 2016, 09:22:27 am »

JNi.media) Israeli Pharmaceutical company Teva appears to be moving into the medical marijuana market, and a pending acquisition could partially relieve the pain of its top drug, Copaxone, going off patent.

Teva, according to a report by The Marker, has made an offer for One World Cannabis (OWC) to purchase the rights to the company’s patents. One World is developing treatments using the compound in cannabis to treat chronic pain, multiple myeloma and other conditions.

OWC recently reported a study by the Sheba Medical Center that showed a 60% reduction of malignant multiple myeloma cells within 24 hours of treatment using the cannabis plant’s active ingredients. OWC is still in the early stages of developing a drug, but the company expects the resultant treatment to be licensed and available by prescription to those patients with myeloma entitled to cannabis-based treatments.

OWC has hired Dr. Yehuda Baruch, former head of Israel’s Ministry of Health’s Cannabis Unit as Director of Research.

Multiple myeloma is the second most common blood cancer after non-Hodgkin lymphoma. It affects six out of every 100,00 people and attacks the white blood cells, which produce antibodies that fight infection. The malignant cancer cells collect in the bone marrow where they disrupt the normal production of white blood cells. The disease is diagnosed by a blood test and is considered incurable but treatable with steroids, chemotherapy or proteasome inhibitors. The survival rate is 45% for five years.

Clay Death · « **Reply #6 on:** November 28, 2016, 03:10:24 pm »

http://www.otcmarkets.com/stock/OWCP/news/OWC-Pharmaceutical-Research-Corp-to-Submit-Psoriasis-Topical-Cream-IRB-Safety-Protocol-to-the-Israeli-National-IRB---quot-Helsinki-quot---Committee?id=144901&b=y

***8K***

Item 1.01. Entry Into A Material Definitive Agreement.

On November 27, 2016, OWC Pharmaceutical Research Corp. (the "Registrant" or "OWCP") and its wholly-owned Israeli subsidiary, One World Cannabis Ltd (OWC Ltd") entered into a license agreement (the "License Agreement") with Emilia Cosmetics Ltd., a company organized under the laws of the State of Israel ("Emilia"), a world-leading company in the field of development, production, manufacturing and packaging of health and beauty products including for treatment of human skin disease. OWCP and OWC Ltd are sometimes referred to collectively as "OWC."

Prior to entering into the License Agreement, the Parties conducted a Development and Evaluation Program (as defined in the License Agreement) for the development of a specific product comprising Emilia's formulation with certain medical cannabis extract provided by OWC Ltd for topical treatment of Psoriasis ("OWC's Product").

Pursuant to the License Agreement, a copy of which is attached hereto as Exhibit 10.19, Emilia has granted a limited license to OWC with respect to Emilia's Licensed Intellectual Property to be developed and commercialized worldwide in the topical treatment of Psoriasis in humans with OWC's Product and upon the successful achievement of the trial, Emilia will grant OWC an exclusive, worldwide, transferable, royalty-bearing license, with the right to grant sublicenses, to use, sell and commercially exploit the Emilia Intellectual Property (the "License"). In consideration for the License, from and after the first commercial sales of the Licensed Product, OWC shall pay to Emilia a royalty at the rate of ten (10%) percent of net sales during the period of time beginning upon the first commercial sale and ending ten (10) years thereafter (the "Royalty Term"). In the event the sale of the Licensed Product during the Royalty Term reaches the minimum sales targets mutually agreed by the Parties as set forth in the License Agreement, the Royalty Term will extend to an additional five (5) year term.
The foregoing descriptions of the License Agreement are qualified in their entirety by reference to the full text of thereof, a copy of which is attached hereto as Exhibit and which is incorporated herein in its entirety by reference.

Divine Metamorphoses · « **Reply #7 on:** December 11, 2016, 01:50:57 am »

Great board and thank you for all the information

Impressive

Clay Death · « **Reply #8 on:** December 17, 2016, 08:42:35 am »

great to see you here lady D.

Clay Death · « **Reply #9 on:** December 27, 2016, 09:19:15 am »

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) engages in the research and development of Cannabis-based medical products. OWCP provides medical products for the treatment of various medical conditions and/or diseases, and provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations. OWC Pharmaceutical conducts medical research and clinical trials through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, PTSD, migraines, and of a unique delivery system.

Clay Death · « **Reply #10 on:** January 11, 2017, 07:44:17 pm »

https://www.insiderfinancial.com/owc-pharmaceutical-research-corp-otcmktsowcp-on-a-bull-run/118980/

Clay Death · « **Reply #11 on:** January 17, 2017, 10:44:35 am »

http://finance.yahoo.com/news/owc-pharmaceutical-research-corp-issues-121500795.html

Clay Death · « **Reply #12 on:** January 21, 2017, 09:53:29 pm »

http://ownthefloat.com/index.php/2017/01/21/owcp-investor-presentation-for-january/

Clay Death · « **Reply #13 on:** January 27, 2017, 08:42:09 pm »

http://oracledispatch.com/2017/01/27/owc-pharmaceutical-research-corp-otcmktsowcp-sets-stage-2017/

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Sets the Stage for 2017
By Jermaine Farmer - January 27, 2017
SHARE Facebook Twitter

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a micro-cap medical marijuana play that has some monster gains under its belt over the past few weeks. And traders have certainly taken notice. Management just hit the wires with its annual letter to the Company’s shareholders to further stoke the flames of enthusiasm for this pre-revenue play.
Perhaps most important to note in the letter were the anticipated action items the company would be looking forward to in 2017: 1. During the second quarter of 2017 OWCP intends to initiate its U.S marketing program for its Psoriasis Topical Cream. At the same time, we intend to begin investigating the applicability of topical cream for other skin conditions and disorders. 2. OWCP intends to proceed with the advancement of our cannabis-based treatment for multiple myeloma, with the objective of proceeding with additional studies. And 3. OWCP intends to evaluate the launch of one or more studies to determine the applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) bills itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.
OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.
All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.
According to company materials, “OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.”

Clay Death · « **Reply #14 on:** January 28, 2017, 07:59:03 pm »

http://mmjreporter.com/owc-pharmaceutical-research-corp-otcmktsowcp-closes-2016-on-a-higher-note-2286.html

CAMELOT FANTASIES

News:

Author Topic: OWCP (Read 2745 times)

Clay Death

OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Divine Metamorphoses

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Clay Death

Re: OWCP

Recent Topics